Does medroxyprogesterone acetate enhance the spinal bone mineral density response to oestrogen in late post-menopausal women?
In osteoporotic post-menopausal women, one year of continuous combined oestrogen/medroxyprogesterone therapy is associated with a 65% greater increment in spinal bone mineral density than is observed in response to unopposed oestrogen. The prescription of combined oestrogen/progestin therapy should be considered in osteoporotic post-menopausal women who have undergone hysterectomy, in order to maximize the skeletal protection provided by hormone replacement therapy.
Quantification of EMT-associated genes in urinary sediment may be a novel approach for searching new biomarkers of DN.